Online inquiry

IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10142MR)

This product GTTS-WQ10142MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CALCA&CALCB gene. The antibody can be applied in Migraine research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001033952.3; NM_000728.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 796; 797
UniProt ID P01258; P10092
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10142MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ6248MR IVTScrip™ mRNA-Anti-RABVgp4, CR57(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CR57
GTTS-WQ14166MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA aIL6R88
GTTS-WQ4876MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BTCT4465A
GTTS-WQ4372MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-188667
GTTS-WQ14665MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SC-003 mAb
GTTS-WQ364MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 20A11-9mer-ALB11
GTTS-WQ9335MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA INCAGN-01876
GTTS-WQ15040MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SRF-231
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW